Improved chemotherapy for hepatocellular carcinoma.
Improved chemotherapy for hepatocellular carcinoma.
复制标题
DOI：
--
复制
发表时间：
2012-04
影响因子：
2
通讯作者：
H. Cao;H. Phan;Li-xi Yang
中科院分区：
文献类型：
--
作者：
H. Cao;H. Phan;Li-xi Yang
肝细胞癌（HCC）是第五大常见癌症，也是全球癌症相关死亡的第三大原因。一旦诊断出患有该疾病，只有30-40%的患者被认为有资格通过包括手术切除、肝移植和化疗栓塞在内的治疗方式进行治愈。最终，大多数患者将接受某种形式的化疗，希望延长生命。索拉非尼是第一个被FDA批准用于治疗晚期HCC的分子抑制剂。它是一种酪氨酸激酶抑制剂，靶向多个分子途径。在索拉非尼出现之前，阿霉素通常作为晚期HCC的单一药物使用，但已显示出无效，反应率约为15- 20%。其他化疗剂，如表阿霉素、顺铂、5-氟尿嘧啶、依托泊苷及其组合，表现出甚至更低的功效。虽然被认为是传统化疗的一个进步，但索拉非尼仅比安慰剂提高了约3个月的预期寿命。考虑到这一点，人们不断努力寻找新的靶点和分子途径，以开发可能的新药。在这篇文章中，我们总结了过去一年中关于晚期肝癌化疗的文献。
Hepatocellular carcinoma (HCC) is the fifth most common cancer and it is the third leading cause of cancer-related deaths worldwide. Once diagnosed with the disease, only 30-40% of patients are deemed eligible for curative intention with treatment modalities including surgical resection, liver transplantation, and chemoembolization. Eventually, most patients will receive some forms of chemotherapy in hope of prolonging life. Sorafenib is the first molecular inhibitor to be approved by the FDA for the treatment of advanced HCC. It is a tyrosine kinase inhibitor, targeting multiple molecular pathways. Prior to the arrival of sorafenib, doxorubicin was routinely used as a single drug for advanced HCC, but has shown inefficacy, with a response rate of about 15-20%. Other chemotherapy agents, such as epirubicin, cisplatin, 5-fluorouracil, etoposide and their combinations, demonstrate even lower efficacy. While being considered an advance over conventional chemotherapy, sorafenib only improves life expectancy approximately by 3 months over placebo. With that in mind, continuous efforts have been put into finding new targets and molecular pathways for possible new drug development. In this article, we summarize the current literature over the past year on chemotherapy treatment of advanced HCC.